In the pooled analysis , 525 of 659 patients ( 79.7 % ) in the dalbavancin group and 521 of 653 ( 79.8 % ) in the vancomycin-linezolid group had an early clinical response indicating treatment success ( weighted difference , -0.1 percentage point ; 95 % confidence interval , -4.5 to 4.2 ) .